A5090208443- Cytokine Signaling Pathways and Interactions
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Wnt/β-catenin signaling in development and cancer
- Lymphoma Diagnosis and Treatment
- Asthma and respiratory diseases
- Kruppel-like factors research
- Cancer-related gene regulation
- Synthesis and biological activity
- Urticaria and Related Conditions
- Computational Drug Discovery Methods
- Systemic Lupus Erythematosus Research
- Lung Cancer Research Studies
- Atherosclerosis and Cardiovascular Diseases
- Quinazolinone synthesis and applications
- Genetics and Neurodevelopmental Disorders
- Synthesis and Reactions of Organic Compounds
- Melanoma and MAPK Pathways
- Cancer-related Molecular Pathways
- IL-33, ST2, and ILC Pathways
- Biochemical and Molecular Research
- Fibroblast Growth Factor Research
Celon Pharma (Poland)
2012-2022
Medical University of Lodz
2012-2015
Queen's University
2012
Up to 10 % of primary gastric cancers are characterized by FGFR2 amplification, and fibroblast growth factor receptor (FGFR) inhibitors may represent therapeutic agents for patients with these malignancies. However, long-term benefits the treatment might be limited owing occurrence drug resistance. To investigate mechanisms resistance selective FGFR inhibitors, we established three FGFR2-amplified SNU-16 cancer cell lines resistant AZD4547, BGJ398, PD173074, respectively. The (SNU-16R)...
Crizotinib, the first FDA-approved ALK inhibitor, showed significant antitumor activity in young patients with anaplastic large-cell lymphoma (ALCL) frequently displaying rearrangement. However, long-term therapeutic benefits of crizotinib are limited due to development drug resistance. CH5424802--more potent and selective inhibitor--comprises a good candidate for second-line treatment crizotinib-relapsed patients. The aim this study was determine possible mechanisms resistance inhibitors...
Phosphoinositide 3-kinase (PI3K) is the family of lipid kinases participating in vital cellular processes such as cell proliferation, growth, migration, or cytokines production. Due to high expression these proteins many human cells and their involvement metabolism regulation, normal embryogenesis, maintaining glucose homeostasis, inhibition PI3K (especially first class which contains four subunits: α, β, γ, δ) considered be a promising therapeutic strategy for treatment inflammatory...
Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment still limited due to suboptimal efficacy and toxicities associated with the available therapies. JAK kinases are well known play an important role systemic erythematous. There growing evidence that ROCK also disease development. In this paper, we present results of development CPL409116, dual inhibitor. The studies performed demonstrate molecule effective inhibitor efficiently blocks progression NZBWF1/J mouse models
TRAF-2 and NCK-interacting kinase (TNIK) is a serine–threonine with proposed role in Wnt/β-catenin JNK pathways.
Phosphoinositide 3-kinase δ (PI3Kδ), a member of the class I PI3K family, is an essential signaling biomolecule that regulates differentiation, proliferation, migration, and survival immune cells. The overactivity this protein causes cellular dysfunctions in many human disorders, for example, inflammatory autoimmune diseases, including asthma or chronic obstructive pulmonary disease (COPD). In work, we designed synthesized new library small-molecule inhibitors based on...
Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result development CPL302-253 molecule, selective PI3Kδ inhibitor. This molecule intended be preclinical candidate for dry powder inhalation in treatment. Studies performed showed that safe and inhibitor can impact many immune functions. We developed short, 15-day HDM induced mouse model, which...
<b>Introduction:</b> Phosphoinositide 3-kinases (PI3K) are lipid kinases involved in multiple biological processes, such as cell proliferation, differentiation and survival. PI3Kδ isoform is expressed predominantly immune cells contributes to innate adaptive responses. It strongly believed that targeting gives a beneficial effect with regard many pathological conditions, autoimmune respiratory diseases including asthma COPD. We developed selective inhibitors great potential be novel drug for...
<b>Introduction:</b> Role of interleukins 4 and 13 was confirmed in allergic asthma pathogenesis driven by Th<sub>2</sub> cells. Both cytokines signal through common γ-chain receptors, associated with JAK/STAT pathway. Janus kinases (JAKs) are responsible for immune signaling response to ligands bound IL-4Rα IL-13Rα receptors. IL-4 involves JAK1/3, IL-13 JAK1/2 mediated activation STAT6 transcription factor related eotaxin-3 (CCL26) expression. Therefore, development JAK inhibitors seems an...